Abstract
The results of a pilot multimodality program (surgery + radiotherapy + chemotherapy) are reported in 34 women with advanced stage III and IV adenocarcinoma of the breast. The median relapse-free survival for all patients was 24 months, with 74% of the premenopausal patients and 37% of the postmenopausal alive at five years (P = 0.18). The relapse rate was significantly lower in premenopausal patients when compared to the postmenopausal subgroup. Estrogen receptor status was not predictive for relapse or survival.
MeSH terms
-
Adenocarcinoma / therapy*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols*
-
Breast Neoplasms / therapy*
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Follow-Up Studies
-
Humans
-
Lymph Node Excision
-
Mastectomy
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Middle Aged
-
Neoplasm Staging
-
Pilot Projects
-
Radiotherapy / adverse effects
-
Receptors, Estrogen / analysis
Substances
-
Receptors, Estrogen
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate